In line with this, the prespecified interim analysis of the phase III NATALEE trial (NCT03701334) shows the benefit of a CDK4/6 inhibitor (ribociclib) in combination with ET compared to ET alone for early stage ER+ BC patients at risk for recurrence37. This evidence concerns the gene CDK4 and breast cancer.